Powered by HealthTechMovers.com
We added 2 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Insulet, PODD
Summary: Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.
- Last Price: $165.04
- Price Change: $5.55, 3.48%
- Yearly Gain: -31.54%
- Market Cap: $11.14B
- P/E Ratio: 177.883
Here are 3rd party ratings for PODD:
- TipRanks.com: Moderate Buy
- TradingView.com: sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 32% (79 out of 246)
What is the sentiment on the street regarding Insulet ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in PODD or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PODD before you decide to make any investment.
Click here for chart >>
Akero Therapeutics, AKRO
Summary: Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.
- Last Price: $45.78
- Price Change: -$4.81, -9.5%
- Yearly Gain: 51.25%
- Market Cap: $2.81B
- P/E Ratio: -19.743
Here are 3rd party ratings for AKRO:
- TipRanks.com: Strong Buy
- TradingView.com: sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 36% (89 out of 246)
What is the sentiment on the street regarding Akero Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in AKRO or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on AKRO before you decide to make any investment.
Click here for chart >>
Thanks for reading!
